vs
Lakeside Holding Ltd（LSH）与瓦里安医疗系统（UTMD）财务数据对比。点击上方公司名可切换其他公司
瓦里安医疗系统的季度营收约是Lakeside Holding Ltd的1.3倍（$9.0M vs $7.0M），瓦里安医疗系统净利率更高（28.4% vs -22.6%，领先51.0%），Lakeside Holding Ltd同比增速更快（95.0% vs -1.2%）
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
瓦里安医疗系统是一家总部位于美国加利福尼亚州帕洛阿尔托的肿瘤放射治疗设备与软件制造商，其产品包括直线加速器以及用于放射治疗、放射外科、质子治疗、短距离放射治疗等癌症及其他病症治疗的相关软件，同时为癌症诊疗中心、放射治疗中心提供运营管理软件，全球员工规模超过7100人。
LSH vs UTMD — 直观对比
营收规模更大
UTMD
是对方的1.3倍
$7.0M
营收增速更快
LSH
高出96.3%
-1.2%
净利率更高
UTMD
高出51.0%
-22.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.0M | $9.0M |
| 净利润 | $-1.6M | $2.6M |
| 毛利率 | 27.2% | 58.2% |
| 营业利润率 | -21.3% | 27.0% |
| 净利率 | -22.6% | 28.4% |
| 营收同比 | 95.0% | -1.2% |
| 净利润同比 | 18.7% | -11.6% |
| 每股收益（稀释后） | $-0.08 | $0.80 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSHUTMD
| Q4 25 | $7.0M | $9.0M | ||
| Q3 25 | $6.1M | $9.8M | ||
| Q2 25 | $6.3M | $10.0M | ||
| Q1 25 | $3.8M | $9.7M | ||
| Q4 24 | $3.6M | $9.2M | ||
| Q3 24 | $4.1M | $10.0M | ||
| Q2 24 | — | $10.4M | ||
| Q1 24 | — | $11.3M |
净利润LSHUTMD
| Q4 25 | $-1.6M | $2.6M | ||
| Q3 25 | $-1.4M | $2.6M | ||
| Q2 25 | $-893.1K | $3.0M | ||
| Q1 25 | $-1.1M | $3.0M | ||
| Q4 24 | $-1.9M | $2.9M | ||
| Q3 24 | $-1.3M | $3.6M | ||
| Q2 24 | — | $3.5M | ||
| Q1 24 | — | $4.0M |
毛利率LSHUTMD
| Q4 25 | 27.2% | 58.2% | ||
| Q3 25 | 18.2% | 57.1% | ||
| Q2 25 | 26.7% | 56.2% | ||
| Q1 25 | 18.8% | 57.0% | ||
| Q4 24 | -1.2% | 58.1% | ||
| Q3 24 | 12.8% | 58.0% | ||
| Q2 24 | — | 60.1% | ||
| Q1 24 | — | 59.7% |
营业利润率LSHUTMD
| Q4 25 | -21.3% | 27.0% | ||
| Q3 25 | -20.8% | 26.6% | ||
| Q2 25 | -8.9% | 32.1% | ||
| Q1 25 | -28.2% | 32.5% | ||
| Q4 24 | -55.6% | 32.0% | ||
| Q3 24 | -32.5% | 33.4% | ||
| Q2 24 | — | 33.1% | ||
| Q1 24 | — | 34.2% |
净利率LSHUTMD
| Q4 25 | -22.6% | 28.4% | ||
| Q3 25 | -22.2% | 26.8% | ||
| Q2 25 | -14.2% | 30.6% | ||
| Q1 25 | -28.2% | 31.3% | ||
| Q4 24 | -54.1% | 31.7% | ||
| Q3 24 | -32.7% | 35.6% | ||
| Q2 24 | — | 33.2% | ||
| Q1 24 | — | 34.9% |
每股收益（稀释后）LSHUTMD
| Q4 25 | $-0.08 | $0.80 | ||
| Q3 25 | $-0.09 | $0.82 | ||
| Q2 25 | $-0.11 | $0.94 | ||
| Q1 25 | $-0.14 | $0.92 | ||
| Q4 24 | $-0.26 | $0.86 | ||
| Q3 24 | $-0.18 | $1.03 | ||
| Q2 24 | — | $0.98 | ||
| Q1 24 | — | $1.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $85.8M |
| 总债务越低越好 | $2.4M | $225.0K |
| 股东权益账面价值 | $12.2M | $119.3M |
| 总资产 | $24.3M | $122.5M |
| 负债/权益比越低杠杆越低 | 0.20× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资LSHUTMD
| Q4 25 | $1.6M | $85.8M | ||
| Q3 25 | $4.5M | $84.3M | ||
| Q2 25 | $5.0M | $82.2M | ||
| Q1 25 | $1.5M | $83.3M | ||
| Q4 24 | $1.1M | $83.0M | ||
| Q3 24 | $2.7M | $88.5M | ||
| Q2 24 | — | $89.2M | ||
| Q1 24 | — | $93.8M |
总债务LSHUTMD
| Q4 25 | $2.4M | $225.0K | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $774.2K | $269.0K | ||
| Q4 24 | $784.8K | $282.0K | ||
| Q3 24 | $589.9K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LSHUTMD
| Q4 25 | $12.2M | $119.3M | ||
| Q3 25 | $7.0M | $118.3M | ||
| Q2 25 | $2.8M | $117.5M | ||
| Q1 25 | $749.8K | $117.0M | ||
| Q4 24 | $1.6M | $117.4M | ||
| Q3 24 | $3.6M | $124.2M | ||
| Q2 24 | — | $124.1M | ||
| Q1 24 | — | $127.7M |
总资产LSHUTMD
| Q4 25 | $24.3M | $122.5M | ||
| Q3 25 | $18.6M | $122.0M | ||
| Q2 25 | $14.4M | $120.8M | ||
| Q1 25 | $9.9M | $122.5M | ||
| Q4 24 | $9.8M | $122.5M | ||
| Q3 24 | $10.8M | $129.7M | ||
| Q2 24 | — | $130.0M | ||
| Q1 24 | — | $135.4M |
负债/权益比LSHUTMD
| Q4 25 | 0.20× | 0.00× | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 1.03× | 0.00× | ||
| Q4 24 | 0.48× | 0.00× | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-453.5K | $3.5M |
| 自由现金流经营现金流 - 资本支出 | — | $3.4M |
| 自由现金流率自由现金流/营收 | — | 37.2% |
| 资本支出强度资本支出/营收 | — | 1.2% |
| 现金转化率经营现金流/净利润 | — | 1.36× |
| 过去12个月自由现金流最近4个季度 | — | $14.3M |
8季度趋势，按日历期对齐
经营现金流LSHUTMD
| Q4 25 | $-453.5K | $3.5M | ||
| Q3 25 | $-4.0M | $3.9M | ||
| Q2 25 | $-483.7K | $2.9M | ||
| Q1 25 | $-238.3K | $4.5M | ||
| Q4 24 | $-530.2K | $2.9M | ||
| Q3 24 | $-1.4M | $3.9M | ||
| Q2 24 | — | $2.8M | ||
| Q1 24 | — | $5.3M |
自由现金流LSHUTMD
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $3.9M | ||
| Q2 25 | $-497.4K | $2.8M | ||
| Q1 25 | — | $4.3M | ||
| Q4 24 | $-560.5K | $2.9M | ||
| Q3 24 | $-1.4M | $3.8M | ||
| Q2 24 | — | $2.7M | ||
| Q1 24 | — | $5.3M |
自由现金流率LSHUTMD
| Q4 25 | — | 37.2% | ||
| Q3 25 | — | 39.2% | ||
| Q2 25 | -7.9% | 28.4% | ||
| Q1 25 | — | 44.1% | ||
| Q4 24 | -15.6% | 32.0% | ||
| Q3 24 | -34.5% | 37.7% | ||
| Q2 24 | — | 25.5% | ||
| Q1 24 | — | 46.3% |
资本支出强度LSHUTMD
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | 0.2% | 0.5% | ||
| Q1 25 | 0.0% | 1.9% | ||
| Q4 24 | 0.8% | 0.1% | ||
| Q3 24 | 0.1% | 0.9% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.2% |
现金转化率LSHUTMD
| Q4 25 | — | 1.36× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 1.47× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.08× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 1.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
UTMD
暂无分部数据
